Invited Paper

New Therapeutic Options for Treatment of Multi-drug Resistant Gram-negative Microorganisms


  • Müge Ayhan

Received Date: 20.01.2020 Accepted Date: 14.05.2020 J Ankara Univ Fac Med 2020;73(2):96-101

Recently, antibiotic resistance in gram-negative microorganisms has been increased. While multi-drug resistant and extensively-drug resistant gram-negative strains are the most common cause of healthcare-associated infections, and they are related with high morbidity and mortality. This increase in antimicrobial resistance results in frequently inappropriate use of antibiotics. Effective antibiotic options are decreasing, in proportion to this, new antibiotic development is less than the resistance. However, datas related with on some newly developed and developing antibiotics, which are included in the old antimicrobial classes, are increasing. In this review, it is aimed to present new antibiotic options that are being used and are being developed for the treatment of infections which are caused by antibiotic resistant gram-negative microorganisms are presented. Double carbapenem therapy has been studied and evaluated as a treatment option for carbapenemase producing Enterobacteriaceae. Ceftazidime -avibactam, meropenem - vaborbactam and ceftolozan - tazobactam, which are new beta-lactam beta-lactamase inhibitors, will soon appear to be included in daily clinical practice. In addition, imipenem/cilastatin - relebactam, eravacycline, plasomycin and cefiderocol are new antibiotics that are still being studied for efficacy and safety. Although, with all these new treatment options, we get stronger against infections that are caused by drug resistant gram-negatives, the best way to combat drug resistant microorganisms is to prevent the resistance and spread of resistant clones the rational use of antibiotics.

Keywords: Gram-negative, Antibiotic Resistance, Carbapenemases, Multi-drug Resistance

Full Text (Turkish)